The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of durvalumab (MEDI4736) and tremelimumab in metastatic, nontransitional cell carcinoma of the urothelial tract.
 
Michal Sarfaty
Honoraria - Novartis; Roche
 
Irina Ostrovnaya
No Relationships to Disclose
 
Min Yuen Teo
Research Funding - Bristol-Myers Squibb; Clovis Oncology
 
Gopa Iyer
Consulting or Advisory Role - Bayer; Janssen; Mirati Therapeutics
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Mirati Therapeutics (Inst); Novartis (Inst)
 
Chung-Han Lee
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Calithera Biosciences; Eisai; Eisai
 
Vanessa Peters
No Relationships to Disclose
 
Jennifer Durocher
No Relationships to Disclose
 
Ashley Marie Regazzi
No Relationships to Disclose
 
Asia S. McCoy
No Relationships to Disclose
 
Grace Hettich
No Relationships to Disclose
 
Hikmat Al-Ahmadie
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; EMD Serono
 
Joshua Chaim
No Relationships to Disclose
 
Dean F. Bajorin
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Merck; Novartis; Pfizer; Roche; Roche/Genentech; Urogen pharma
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Roche/Genentech; Urogen pharma
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Clinical Care Options; ClinicalMind; Intellisphere; Medscape; Peerview; Research To Practice; UpToDate; Vindico
Consulting or Advisory Role - Adicet Bio; Agensys; Astellas Pharma; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Bristol-Myers Squibb; EMD Serono; Fortress Biotech; GlaxoSmithKline; Inovio Pharmaceuticals; Janssen Oncology; Lilly; Merck; Pharmacyclics; QED Therapeutics; Roche/Genentech; Seagen; Sensei Biotherapeutics; western oncolytics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); QED Therapeutics (Inst); Seagen (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche
 
Samuel Aaron Funt
Stock and Other Ownership Interests - Allogene Therapeutics; Hubble (I); Kite, a Gilead company; Kronos Bio (I); Neogene Therapeutics (I); Second Science; Urogen pharma (I); Vida Ventures (I)
Consulting or Advisory Role - AstraZeneca/MedImmune (Inst)
Research Funding - AstraZeneca (Inst); Decibel Therapeutics (Inst); Genentech/Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb